BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND GNAS, RP4-543J19_4, 2778, ENSG00000087460, NESP55, NESP, GSP, POH, GNASXL, GNAS1, C20orf45, dJ309F20_1_1, SCG6, GPSA, Gnas, dJ806M20_3_3, XL2, MGC33735, XL, PHP1A, GSA, AHO, XLalphas, PHP1B AND Treatment
8741 results:

  • 1. Epithelial ovarian cancer and brain metastases: might the
    Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
    Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The Impact of Mitochondria in ovarian cancer Cell Metabolism, Proliferation, and Metastasis.
    Schatten H
    Adv Exp Med Biol; 2024; 1452():119-125. PubMed ID: 38805128
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Tubulin Complexity in cancer and Metastasis.
    Danziger M; Xu F; Noble H; Yang P; Roque DM
    Adv Exp Med Biol; 2024; 1452():21-35. PubMed ID: 38805123
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Analysis of sequential chemotherapy efficacy in ovarian epithelial carcinoma, fallopian tube carcinoma and primary peritoneal carcinoma].
    Shen XY; Li XP; Wang Y; Wu Y; Li Y; Yang YC; Wei LH; Fan Y; Tang ZQ
    Zhonghua Fu Chan Ke Za Zhi; 2024 May; 59(5):383-390. PubMed ID: 38797568
    [No Abstract]    [Full Text] [Related]  

  • 5. Synchronous skull base and spinal metastases in a patient with treatment-resistant, high-grade serous adenocarcinoma of tubo-ovarian origin.
    Ziegler J; El-Shakankery KH; Hyare H; Flynn M
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772871
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Racial and Ethnic Inequities in cancer Care Continuity During the COVID-19 Pandemic Among Those With SARS-CoV-2.
    Islam JY; Hathaway CA; Hume E; Turner K; Hallanger-Johnson J; Tworoger SS; Camacho-Rivera M
    JAMA Netw Open; 2024 May; 7(5):e2412050. PubMed ID: 38767916
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Mirvetuximab soravtansine: A breakthrough in targeted therapy for platinum-resistant ovarian cancer.
    Kokori E; Olatunji G; Komolafe R; Abraham IC; Ukoaka B; Samuel O; Ayodeji A; Ogunbowale I; Ezenwoba C; Aderinto N
    Medicine (Baltimore); 2024 May; 103(20):e38132. PubMed ID: 38758856
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant ovarian cancer: Findings From Cohort A of the OPAL Phase II Trial.
    Liu JF; Gaillard S; Wahner Hendrickson AE; Yeku O; Diver E; Gunderson Jackson C; Arend R; Ratner E; Samnotra V; Gupta D; Chung J; Zhang H; Compton N; Baines A; Bacqué E; Liu X; Felicetti B; Konecny GE
    JCO Precis Oncol; 2024 May; 8():e2300693. PubMed ID: 38754056
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. The Role of Palliative Surgery in the Management of Acute Intestinal Obstruction Secondary to Peritoneal Carcinomatosis.
    Bhat BK; Yadav A; Nundy S
    Chirurgia (Bucur); 2024 Apr; 119(2):218-226. PubMed ID: 38743835
    [No Abstract]    [Full Text] [Related]  

  • 10. Vitamins in Gynecologic Malignancies.
    Wierzbowska N; Olszowski T; Chlubek D; Kozłowski M; Cymbaluk-Płoska A
    Nutrients; 2024 May; 16(9):. PubMed ID: 38732639
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
    Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
    Trials; 2024 May; 25(1):301. PubMed ID: 38702828
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
    Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
    J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Exceptional lymph node recurrence of an unusual ovarian tumor 16 years later: a case report.
    Sakhri S; Slimane M; Bouaziz H; Khessairi N; Boujelbene N; Ben Dhiab T
    J Med Case Rep; 2024 Apr; 18(1):217. PubMed ID: 38654310
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
    Friedman CF; Manning-Geist BL; Zhou Q; Soumerai T; Holland A; Da Cruz Paula A; Green H; Ozsoy MA; Iasonos A; Hollmann T; Leitao MM; Mueller JJ; Makker V; Tew WP; O'Cearbhaill RE; Liu YL; Rubinstein MM; Troso-Sandoval T; Lichtman SM; Schram A; Kyi C; Grisham RN; Causa Andrieu P; Wherry EJ; Aghajanian C; Weigelt B; Hensley ML; Zamarin D
    Nat Med; 2024 May; 30(5):1330-1338. PubMed ID: 38653864
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Granulosa cell tumor of the ovary: a series of 6 cases.
    da Costa REAR; Silva MCA; Cavalcante ECX; Branco ROC; Dos Reis CA; Vieira SC
    Pan Afr Med J; 2024; 47():58. PubMed ID: 38646138
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
    Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Small bite fascial closure technique reduces incisional hernia rates in gynecologic oncology patients.
    Straubhar AM; Stroup C; Manorot A; McCool K; Rolston A; Reynolds RK; McLean K; de Bear O; Siedel J; Uppal S
    Int J Gynecol Cancer; 2024 May; 34(5):745-750. PubMed ID: 38642924
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Imaging for local recurrence of breast cancer.
    Schlaiss T; Bott L; Herbert SL; Bartmann C; Kiesel M; Salmen J; Sauer ST; Christner SA; Petritsch B; Grunz JP; Woeckel A; Löb S; Diessner J
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):200. PubMed ID: 38627285
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
    Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
    Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A New Model Including AMH Cut-off Levels to Predict Post-treatment ovarian Function in Early Breast cancer: A Prospective Cohort Study.
    Omranipour R; Ahmadi-Harchegani F; Saberi A; Moini A; Shiri M; Jalaeefar A; Arian A; Seifollahi A; Madani M; Eslami B; Alipour S
    Arch Iran Med; 2024 Feb; 27(2):96-104. PubMed ID: 38619033
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 438.